Analyst Ranking
Bottom 7%
#4905 out of 5266 analysts
Average Return
-3.07%
Win Rate
35%33 out of 95
Risk vs Reward
Poor
Good

Thomas Shrader's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Ovid Therapeutics IncOVID
+474.32%$0.44$2.55
2025-03-23 -
2026-03-23
Strong Buy
Annexon IncANNX
+136.19%$2.10$4.96
2023-05-24 -
2024-05-24
Strong Buy
Opus Genetics IncIRD
+127.43%$2.26$5.14
2026-01-19 -
2026-05-01
Strong Buy
Inmune Bio IncINMB
+117.73%$10.38$22.60
2020-08-31 -
2021-08-30
Strong Buy
Biohaven LtdBHVN
+101.08%$16.74$33.66
2022-12-01 -
2023-12-01
Strong Buy

Thomas Shrader Analyst Color

Get additional color on Thomas Shrader's coverage of popular stocks

Thomas Shrader's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neonc Technologies Holdings IncNTHI
1Strong Buy$15.00+269.46%Initiates Coverage On
9 days ago
Compass Pathways PLCCMPS
2Strong Buy$14.00+55.38%Reiterates
13 days ago
Harrow IncHROW
5Strong Buy$63.00+54.03%Reiterates
16 days ago
Bright Minds Biosciences IncDRUG
5Strong Buy$147.00N/AReiterates
a month ago
Acumen Pharmaceuticals IncABOS
5Strong Buy$8.00+236.13%Reiterates
a month ago
Ovid Therapeutics IncOVID
4Strong Buy$4.00+43.37%Reiterates
a month ago
Denali Therapeutics IncDNLI
5Strong Buy$38.00+107.65%Maintains
a month ago
Nrx Pharmaceuticals IncNRXP
4Strong Buy$25.00+709.06%Reiterates
a month ago
Stoke Therapeutics IncSTOK
3Strong Buy$39.00+17.90%Reiterates
a month ago
Ac Immune SaACIU
4Strong Buy$8.00+168.46%Reiterates
2 months ago
Alector IncALEC
4Strong Buy$6.00+154.24%Upgrades
2 months ago
Opus Genetics IncIRD
3Strong Buy$12.00+133.46%Maintains
2 months ago
Invivyd IncIVVD
3Strong Buy$10.00+557.89%Reiterates
2 months ago
Vaxcyte IncPCVX
8Strong Buy$89.00+56.33%Maintains
2 months ago
Alto Neuroscience IncANRO
2Strong Buy$28.00+12.27%Maintains
3 months ago
Novavax IncNVAX
1Strong Buy$19.00+136.32%Reiterates
3 months ago
Biohaven LtdBHVN
4Strong Buy$16.00+66.15%Reiterates
5 months ago
Coya Therapeutics IncCOYA
3Strong Buy$16.00+283.69%Maintains
6 months ago
Aldeyra Therapeutics IncALDX
2Strong Buy$9.00+466.04%Reiterates
6 months ago
Arcturus Therapeutics Holdings IncARCT
2Strong Buy$23.00+166.51%Maintains
6 months ago
Gain Therapeutics IncGANX
4Strong Buy$9.00+378.72%Reiterates
7 months ago
Promis Neurosciences IncPMN
1Strong Buy$200.00N/AInitiates Coverage On
3 years ago
Precision Biosciences IncDTIL
1Strong Buy$60.00N/AMaintains
3 years ago
Annexon IncANNX
2Strong Buy$7.00N/AMaintains
3 years ago
Leonabio IncLONA
2Strong Buy$100.00N/AMaintains
3 years ago
Bioatla IncBCAB
3Strong Buy$650.00N/AMaintains
3 years ago
Verona Pharma PLCVRNA
3Strong Buy$31.00N/AMaintains
3 years ago
Sqz Biotechnologies CoSQZB
2Strong Buy$15.00N/AMaintains
4 years ago
Inmune Bio IncINMB
2Strong Buy$14.00N/AMaintains
4 years ago
Sigilon Therapeutics IncSGTX
1Strong Buy$182.00N/AInitiates Coverage On
5 years ago
Pliant Therapeutics IncPLRX
1Strong Buy$51.00N/AInitiates Coverage On
5 years ago
Celularity IncCELU
1Strong Buy$16.00N/AInitiates Coverage On
5 years ago
Oncosec Medical IncONCSQ
1Strong Buy$220.00N/AInitiates Coverage On
5 years ago
Nuvation Bio IncNUVB
1Strong Buy$16.00N/AInitiates Coverage On
5 years ago
Voyager Therapeutics IncVYGR
1HoldN/AN/ADowngrades
5 years ago
Eidos Therapeutics IncEIDX
1HoldN/AN/ADowngrades
5 years ago
89bio IncETNB
1Strong Buy$58.00N/AMaintains
6 years ago
Checkmate Pharmaceuticals IncCMPI
1Strong Buy$29.00N/AInitiates Coverage On
6 years ago
Geron CorpGERN
1Strong Buy$3.00N/AMaintains
6 years ago
Acorda Therapeutics IncACORQ
1Hold$840.00N/AMaintains
7 years ago
Biogen IncBIIB
3Hold$346.00N/ADowngrades
7 years ago
Momenta Pharmaceuticals IncMNTA
2Strong BuyN/AN/AUpgrades
8 years ago
Kite Pharma IncKITE
1HoldN/AN/ADowngrades
9 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.